The Markey Cancer Center (MCC) Protocol Review and Monitoring System (PRMS) provides thorough review of clinical trials for scientific validity, feasibility and prioritization within the clinical trials portfolio and monitoring of scientific progress. The PRMS must approve all interventional cancer research prior to study initiation and has the authority to recommend closure of trials for lack of scientific progress or patient accrual. The PRMS provides a framework which aims to balance appropriate resource utilization while maximizing the opportunities for current and future patients with cancer in this region to participate in clinical trials, including the underserved area of Appalachian Kentucky. The development of novel MCC investigator-initiated clinical trials and participation in high-priority national trials provide a robust portfolio of therapeutic research studies available to MCC patients.
The patients of the MCC represent a diverse population with the highest incidence rates of lung and colorectal cancers in the United States, high rates of poverty and increased rates of important risk behaviors (i.e., smoking and low screening rates for some cancers). These challenges require a well-developed PRMS to facilitate effective clinical and translational trials to overcome the health disparities of this region and lead to improvement in cancer survival.
|Gedaly, Roberto; De Stefano, Felice; Turcios, Lilia et al. (2018) mTOR Inhibitor Everolimus in Regulatory T cell Expansion for Clinical Application in Transplantation. Transplantation :|
|Pi, Fengmei; Binzel, Daniel W; Lee, Tae Jin et al. (2018) Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression. Nat Nanotechnol 13:82-89|
|Wang, Qingding; Zhou, Yuning; Rychahou, Piotr et al. (2018) Deptor Is a Novel Target of Wnt/?-Catenin/c-Myc and Contributes to Colorectal Cancer Cell Growth. Cancer Res 78:3163-3175|
|Rychahou, Piotr; Bae, Younsoo; Reichel, Derek et al. (2018) Colorectal cancer lung metastasis treatment with polymer-drug nanoparticles. J Control Release 275:85-91|
|Kosmac, Kate; Peck, Bailey D; Walton, R Grace et al. (2018) Immunohistochemical Identification of Human Skeletal Muscle Macrophages. Bio Protoc 8:|
|Frohman, Heather A; Rychahou, Piotr G; Li, Jing et al. (2018) Development of murine bariatric surgery models: lessons learned. J Surg Res 229:302-310|
|Chaiswing, Luksana; St Clair, William H; St Clair, Daret K (2018) Redox Paradox: A Novel Approach to Therapeutics-Resistant Cancer. Antioxid Redox Signal 29:1237-1272|
|Chauhan, Aman; Farooqui, Zainab; Murray, Le Aundra et al. (2018) Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary. J Oncol 2018:3519247|
|Zhang, Xiaofei; Zhang, Yi; Han, Erik Y et al. (2018) Classification of Whole Mammogram and Tomosynthesis Images Using Deep Convolutional Neural Networks. IEEE Trans Nanobioscience 17:237-242|
|Li, Jing; Song, Jun; Li, Xian et al. (2018) FFAR4 Is Involved in Regulation of Neurotensin Release From Neuroendocrine Cells and Male C57BL/6 Mice. Endocrinology 159:2939-2952|
Showing the most recent 10 out of 359 publications